Examining Best Practices for Specialty Pharmacists to Improve the Care of Patients With α1-Antitrypsin Deficiency

Specialty Pharmacy Times, June 2020, Volume 3, Issue 2

This continuing education activity is supported by an educational grant from CSL Behring.

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM CSL BEHRING.

Faculty

Mark A. Malesker, PharmD, FCCP, FCCM, FASHP, BCPS, Professor of Pharmacy Practice and Medicine at Creighton University in Omaha, Nebraska

Lee E. Morrow, MD, FCCP, ATF, MSc, Professor of Medicine in the Division of Pulmonary and Critical Care at Creighton University, Chief of Pulmonary and Critical Care at Nebrasks-Western Iowa VA Medical Center in Omaha, Nebrasksa

At the completion of this activity, the participant will be able to:

  • Explain the hereditary basis, pathophysiology, and diagnostic challenges of α₁-antitrypsin deficiency (AATD)
  • Investigate the available therapies for AATD by understanding key characteristics including mechanism of action and efficacy
  • Examine the dosing, preparation, and administration of available therapies for AATD
  • Identify key counseling points for effective communication with patients receiving augmentation therapy for AATD

TARGET AUDIENCE: Pharmacists

ACTIVITY TYPE:Application

RELEASE DATE: December 20, 2019

EXPIRATION DATE: June 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.